- Home
- CCB vs AVTX Comparison
CCB vs AVTX Comparison
Compare CCB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCB | AVTX |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 956.7M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CCB | AVTX |
|---|---|---|
| Price | $45.34 | $18.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $126.67 | $40.57 |
| AVG Volume (30 Days) | 335.2K | ★ 835.6K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $96.61 | N/A |
| Revenue Next Year | $22.66 | N/A |
| P/E Ratio | $56.32 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $36.61 | $8.29 |
| 52 Week High | $120.05 | $24.27 |
Technical Indicators
Market Signals| Indicator | CCB | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 20.59 | 52.08 |
| Support Level | $36.61 | $17.32 |
| Resistance Level | $82.21 | $19.21 |
| Average True Range (ATR) | 3.91 | 1.19 |
| MACD | -3.36 | -0.12 |
| Stochastic Oscillator | 16.99 | 46.75 |
Price Performance
Historical ComparisonAbout CCB Coastal Financial Corporation
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.